Journal Of Biopharmaceutical Statistics

雜志介紹

Journal Of Biopharmaceutical Statistics雜志介紹

《Journal Of Biopharmaceutical Statistics》是一本以English為主的未開放獲取國際優秀期刊，中文名稱生物制藥統計雜志，本刊主要出版、報道醫學-PHARMACOLOGY & PHARMACY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為1.2，最新CiteScore 指數為2.5。

本刊近期中國學者發表的論文主要有：

• Confidence intervals of mean residual life function in length-biased sampling based on modified empirical likelihood

  Author: Ratnasingam, Suthakaran; Ning, Wei

• Risk difference, relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpoint

  Author: Ni, Senmiao; Yu, Quanji; Zhong, Zihang; Yang, Min; Zhao, Yang; Wu, Jingwei; Bai, Jianling; Yu, Hao

• A randomized Bayesian optimal phase II design with binary endpoint

  Author: Ding, Yang

• Modelling non-linear patterns of time-varying intervention effects on recurrent events in infectious disease prevention studies

  Author: Cheung, Yin Bun; Ma, Xiangmei; Lam, K. F.; Yung, Chee Fu; Milligan, Paul

英文介紹

Journal Of Biopharmaceutical Statistics雜志英文介紹

The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:

Drug, device, and biological research and development;

Drug screening and drug design;

Assessment of pharmacological activity;

Pharmaceutical formulation and scale-up;

Preclinical safety assessment;

Bioavailability, bioequivalence, and pharmacokinetics;

Phase, I, II, and III clinical development including complex innovative designs;

Premarket approval assessment of clinical safety;

Postmarketing surveillance;

Big data and artificial intelligence and applications.